HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2 , MAP4K5, IRAK1 , NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC 50 values of 8.25, 29, 33, 63,
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in